Nicergolină Lph (Nicergoline)

Nicergoline antagonizes alpha‑adrenergic receptors, causing dilation of cerebral and peripheral vessels. It also promotes nitric oxide release from the endothelium and inhibits platelet aggregation, which together enhance microcirculatory blood flow and improve oxygen delivery to affected tissues.

The prescribed dose of Nicergolină Lph is determined by the treating physician based on the individual’s clinical condition, age, and response to therapy. Dosage regimens may vary, and patients should follow the prescriber’s instructions without self‑adjusting the amount.

Safety data for nicergoline during pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nicergoline is an ergot‑derived vasodilator, distinct from agents such as pentoxifylline or cilostazol, which act primarily through phosphodiesterase inhibition. Compared with other ergot alkaloids, nicergoline has a lower propensity for severe vasospasm but shares similar mechanisms of alpha‑adrenergic antagonism and platelet inhibition.

Nicergolină Lph should be stored at ambient temperature below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to extreme temperatures.

Nicergolină Lph is taken orally, usually with a glass of water. It may be administered with or without food, but patients should follow the prescriber’s guidance regarding timing relative to meals to minimize gastrointestinal discomfort.

Serious adverse events, though rare, include significant hypotension, hepatic enzyme elevation, cardiac arrhythmias, and severe allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience symptoms like fainting, chest pain, jaundice, or widespread rash.

Nicergoline is contraindicated in patients with known hypersensitivity to ergot alkaloids, uncontrolled hypertension, active coronary artery disease, severe hepatic impairment, and in individuals who are pregnant or breastfeeding unless clearly indicated. It should also be avoided in patients taking other ergot derivatives.